Powered By Inc42 BrandLabs

Powered By Inc42 BrandLabs

Pune-based online platform for healthcare professionals from India, DocPlexus.in, has raised over $700 K (INR 4.6 Cr) from Uniqorn ventures and Austria based ASP Consulting.

With the newly raised funds the startup looks at capturing medical professionals around the market to develop a strong medical networking market and launch its product on iOS.

Presently, DocPlexus is available on web and Android app.

According to Phanish Chandra, founder of DocPlexus, “We have already captured about 20% of Indian allopathic practitioners, and for now we are just focused on practitioners of modern medicine. MCI claims that there are near about 650, 000 doctors in India, and as of now we have captured around 110,000 doctors on our platform. This is almost to 17% of it. Our aim is to reach 150,000 by March next year, in order to build a strong medical networking platform.”

Powered By Inc42 BrandLabs

Powered By Inc42 BrandLabs

Incepted in 2014 by Phanish Chandra, DocPlexus is an online platform for healthcare professionals from India. The platform helps doctors make better medical decisions by giving them a platform to communicate with peers, secure collaboration for patient treatment and medical updates.


DocPlexus platform gives access to an extensive and refined network of medical professionals with 110000 Indian doctors as its members.

Phanish added that DocPlexus is presently a networking and discussion forum for professional discussion. However, moving forward the startup aims at building products for doctors’ community by adding products like online CMEs, certificate courses and some products to bridge the gap between pharma and Indian doctors in next six months.

The startup faces strong competition from players like Curofy and PlexusMD.

Welcome to Flash Feed, your essential source for breaking news and innovation from around the web – bite-sized and updated all day.

Note: We at Inc42 take our ethics very seriously. More information about it can be found here.